Skip to content
Search
AI Powered
Latest Stories

Philip Morris sells inhaler maker business Vectura for nearly £300m

Philip Morris sells inhaler maker business Vectura for nearly £300m
The research and development campus of Philip Morris International, in Neuchatel, western Switzerland. (FABRICE COFFRINI/AFP via Getty Images/File Photo)

Vectura Fertin Pharma, an affiliate of Philip Morris International (PMI), has on Tuesday announced the sale of its subsidiary Vectura Group to global electronics major Molex Asia Holdings for £298 million.

Vectura, based in Chippenham, UK, will be operated by Phillips Medisize, a Molex company and a leader in the design, engineering and manufacturing of pharmaceutical drug delivery, in vitro diagnostic and medtech devices.


PMI, which acquired Vectura in 2021 amid strident opposition from health groups, has also announced the establishment of master service agreements to develop Vectura Fertin Pharma’s inhaled therapeutics proprietary pipeline.

The tobacco giant created Vectura Fertin Pharma as an autonomous unit, bringing together Vectura and Danish company Fertin Pharma, which it acquired in 2020, as part of its plan to go ‘smoke-free’ and switch to healthcare and wellness products.

PMI, which fought off private equity firm Carlyle Group for the roughly 1-billion-pound buyout of Vectura, would receive an upfront cash consideration of £150 million, subject to customary purchase price adjustments, and potential deferred payments of up to £148 million.

Jacek Olczak, PMI chief executive, said Vectura has enabled them to develop a proprietary pipeline of inhaled therapeutics, adding that the business remains committed to driving innovation in this space “over the long-term”.

“With its experience in pharmaceutical drug delivery devices and its global manufacturing footprint, Phillips Medisize is best placed to lead Vectura into the future— while releasing it from the unreasonable burden of external constraints and criticism related to our ownership,” Olczak added.

During the takeover, PMI had faced resistance from public health experts who questioned whether a tobacco group should own a company that cures the respiratory illnesses which cigarettes cause.

PMI said the “unwarranted opposition” to its ownership has impacted Vectura’s scientific engagement and commercial CDMO (contract development and manufacturing organisation) relationships.

The remaining units of Vectura Fertin Pharma will continue to operate as a separate company under PMI’s ownership and will be given a new corporate identity. This business will focus on developing and commercialising oral consumer health and wellness offerings and inhaled prescription products for therapy areas that include pain management and cardiovascular emergencies.

Paul Chaffin, president of Phillips Medisize, said adding the Vectura team will enhance their ability to deliver a broader portfolio of inhalation combination drug devices and solutions to their pharmaceutical customers.

“With our global reach, manufacturing scale, and engineering expertise, Phillips Medisize is uniquely positioned to help Vectura in developing innovative new products for their customers, ultimately benefiting people who suffer with chronic and acute diseases such as asthma and COPD.”

Vectura brings to Phillips Medisize its unique inhalation expertise that includes formulation and device development for dry powder inhalers (DPI), pressurized metered dose inhalers (pMDI), nasal and nebuliser products for small molecules, biologics, complex combinations and generic products. The company also offers pharmaceutical analysis, process development, technical transfer, clinical trial supplies and regulatory services.

“The acquisition of Vectura is the latest step in building an industry-leading capability in medical. It also demonstrates Molex’s commitment to acquiring opportunities to better serve market needs across our portfolio,” said Joe Nelligan, chief executive of Molex, which acquired Phillips Medisize in 2016 to build a scale healthcare business.

“We are excited by the significant growth potential that comes with a wider range of formulation, device design, combination product development and manufacturing services to support the increasing need for inhalation therapies. We look forward to welcoming the Vectura team, who brings a celebrated reputation of inhalation expertise and experience.”

The acquisition is expected to close by the end of 2024, subject to regulatory approvals and other customary closing conditions.

More for you

Brits divided on acceptability of shoplifting,YouGov Poll

Brits divided on acceptability of shoplifting.

iStock image

Brits divided on acceptability of shoplifting amid rising retail crime

Some Brits believe that shoplifting can be acceptable, states a recent report, despite the country experiencing an epidemic of store thefts.

According to a recent YouGov poll of 2,150 adults, 40 per cent of the public agreed that shoplifting food was sometimes acceptable if a person could not afford the goods. More than half of those asked (51 per cent) said it was never acceptable.

Keep ReadingShow less
Footfall increased in January 2025.

Footfall increased in January 2025.

(Photo by Christopher Furlong/Getty Images)

Footfall increased in January as shoppers head to stores: BRC

Shopper footfall received a welcome boost as many consumers hit the January sales in their local community, shows recent data, bringing a welcome news for high streets following a particularly difficult Golden Quarter to end 2024.

According to BRC-Sensormatic data released today (7), total UK footfall increased by 6.6 per cent in January (YoY), up from -2.2 per cent in December.

Keep ReadingShow less
New Ann Forshaw’s Milk Shed launches at SPAR Derwent in Keswick

New Ann Forshaw’s Milk Shed launches at SPAR Derwent in Keswick

SPAR Derwent shakes things up with new Milk Shed

SPAR Derwent in Keswick has become the latest store to introduce an Ann Forshaw’s Milk Shed, bringing fresh whole milk and delicious flavoured milkshakes to the local community.

The new Milk Shed follows successful launches at Ann Forshaw’s Alston Dairy and SPAR stores in Burnley and Milnthorpe.

Keep ReadingShow less
SPAR Cavehill celebrates former owner’s 70th birthday

SPAR Cavehill raised funds for Community Fire & Rescue Service as part of former owner’s 70th birthday celebrations

SPAR Cavehill celebrates former owner’s 70th birthday with charity fundraiser

Belfast’s SPAR Cavehill closed out 2024 with a heartwarming community celebration, marking the 70th birthday of former store owner Norman Porter while raising £800 for two local charities.

The event, organised by the store’s current owners, Frank Quigley and Norman’s daughter, Jenny Reilly, brought together staff, customers, and local residents to celebrate the milestone birthday and support SPAR’s charity partner, Marie Curie, as well as the Community Fire & Rescue Service.

Keep ReadingShow less
IQOS heat-not-burn device and a Marlboro cigarette pack

IQOS heat-not-burn device and a Marlboro cigarette pack

REUTERS/Carlo Allegri/Illustration/File Photo

PMI projects up to 12.5 per cent profit growth for 2025 amid strong smoke-free expansion

Philip Morris International (PMI) has forecast an increase of up to 12.5 per cent in adjusted diluted EPS for 2025, following a strong financial performance in 2024, driven by the continued expansion of its smoke-free product portfolio.

The company delivered a reported diluted EPS of $4.52 (£3.63), or $6.01 before a Canada non-cash impairment of $1.49, compared to $5.02 in 2023. Adjusted diluted EPS reached $6.57, representing growth of 9.3 per cent, and 15.6 per cent on a currency-neutral basis.

Keep ReadingShow less